Related Experiment Video
Updated: May 12, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Is it time for biosimilars in autoimmune diseases?
Maria-Jose Cuadrado1, Savino Sciascia, Xavier Bosch
1Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK. mjcuadrado@yahoo.com
Autoimmunity Reviews
|April 2, 2013
Summary
Biological agents have revolutionized autoimmune disease treatment but are costly. Biosimilars offer a more affordable alternative, prompting a review of their efficacy, safety, and regulation for autoimmune conditions.
Area of Science:
- Immunology
- Pharmacology
- Health Economics
Background:
- Biological agents are now standard treatment for autoimmune diseases, improving patient outcomes.
- The high cost of biological agents presents a significant challenge in healthcare.
- Patent expiries of major biologic drugs create an opportunity for alternatives.
Purpose of the Study:
- To review the efficacy of biosimilars in treating autoimmune diseases.
- To assess the safety profile of biosimilars for autoimmune conditions.
- To examine the regulatory landscape for upcoming biosimilars.
Main Methods:
- Literature review of clinical studies on biosimilar efficacy and safety.
- Analysis of regulatory guidelines from major health authorities.
- Economic evaluation of biosimilars versus reference biological agents.
Main Results:
- Biosimilars demonstrate comparable efficacy to reference biologics in autoimmune diseases.
- Safety profiles of biosimilars are consistent with their reference products.
- Regulatory pathways are established for biosimilar approval, ensuring quality and interchangeability.
Conclusions:
- Biosimilars represent a viable and cost-effective option for managing autoimmune diseases.
- Continued monitoring of efficacy and safety is essential for long-term use.
- Biosimilars are expected to increase patient access to advanced biologic therapies.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...